Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion

• Status: Unknown status
• Trial end date: 2021-06-15
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective, open-label , multicenter randomized controlled trial, with 248 cases in 50 centers planned for a period of 2 years. The aim of the study is to evaluate the safety and effectiveness of microparticles packaging chemotherapeutic drugs (MPCD) therapy on the treatment of malignant pleural effusion (MPE) in patients with advanced lung cancer or breast cancer.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking Union Medical College
• Treatments: Aldesleukin; Interleukin-2; Methotrexate

Criteria

Inclusion Criteria:

1. Histologically confirmed as lung cancer or breast cancer;

2. Cytologically or histologically confirmed MPE needing thoracocentesis treatment;

3. Without thoracocentesis treatment within 4 weeks;

4. ECOG PS score: 0-2 points;

5. Predicted life expectancy greater than 3 months;

6. 18 years ≤Age ≤80 years；

7. Bone marrow function: hemoglobin(HGB) ≥90g/L，white blood cells(WBC) ≥3.0×10^9/L，absolute neutrophil count(ANC) ≥1.5×10^9/L，platelets (PLT) ≥80×10^9/L，international standardized ratio (INR) <1.5;

8. Hepatic function：alanine aminotransferase(ALT) and aspartate aminotransferase(AST) ≤2.5×ULN，serum total bilirubin≤1.5× ULN;

9. Renal function：blood urea nitrogen(BUN) and serum creatinine(Cr) ≤1.5×ULN, or endogenous creatinine clearance rate(Ccr) ≥60mL/min;

10. Without other severe cardiac disease or respiratory disease;

11. The volunteers voluntarily join the study, sign informed consent, and have good compliance and follow-up.

Exclusion Criteria:

1. Inappropriate to receive chemotherapy;

2. Women who are pregnant, preparing to be pregnant, breastfeeding;

3. Known or suspected hypersusceptibility to any agents used in the treatment protocol;

4. With severe cardiac disease, respiratory disease, liver disease, kidney disease, or diabetes;

5. With severe infection;

6. With severe encapsulated pleural effusion or intrathoracic tissue adhesion which is inappropriate to receive thoracocentesis;

7. With cognitive impairment or low compliance;

8. Participating in other clinical trials within 4 weeks;

9. Undergoing immunotherapy within 3 months;

10. Other conditions considered to be inappropriate to be enrolled by the investigator.